

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., DR. REDDY'S LABORATORIES, INC.,
DR. REDDY'S LABORATORIES, LTD., SUN PHARMACEUTICAL
INDUSTRIES LTD., AND SUN PHARMACEUTICAL INDUSTRIES, INC.

Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case No. IPR2023-00724¹

Patent No. 10,335,462

PETITIONER'S REQUEST FOR ORAL ARGUMENT

¹ IPR2024-00009 (Dr. Reddy's Laboratories) and IPR2024-00107 (Sun Pharmaceutical Industries) have been joined with this proceeding.

Pursuant to 37 C.F.R. § 42.70(a) and the Board's Scheduling Order, Petitioner Mylan Pharmaceuticals Inc. respectfully requests oral argument, which is currently scheduled for August 27, 2024. Paper 64, 3.

Petitioner intends to argue the following issues:

1. Any issues addressed by Petitioner, including those raised in the Petition for Inter Partes Review, Petitioner's Reply, and any related exhibits, including issues relating to whether claims 1-10 are unpatentable for anticipation and/or obviousness.
2. Any issues properly raised by Patent Owner, including those raised in Patent Owner's Response, Patent Owner's Sur-Reply, and any related exhibits.
3. Rebuttal to issues raised by Patent Owner.
4. Any Motions to Exclude Evidence by Petitioner, as well as Oppositions and Replies thereto.
5. Any Motions to Exclude Evidence by Patent Owner, as well as Oppositions and Replies thereto.
6. Any issues properly raised in Patent Owner's Request for Oral Argument.
7. Any other issues raised in papers filed in this proceeding or on which the Board seeks information or clarification.

Petitioner requests that each side have forty-five (45) minutes for oral

argument. Petitioner requests that oral argument be conducted in person, subject to the Board's guidance. In the event that the hearing is conducted in person, Petitioner requests the ability to use audio/visual equipment to display demonstrative exhibits, including the use of a projector and screen for a PowerPoint presentation.

Dated: July 12, 2024

Respectfully submitted,

PERKINS COIE LLP
700 Thirteenth Street, N.W., Suite 800
Washington, D.C. 20005-3960
202.654.6200 (phone)
202.654.6211 (fax)

/Brandon M. White/
Lead Counsel
Brandon M. White, Reg No. 52,354

Attorneys for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served a true and correct copy of the foregoing: PETITIONER'S REQUEST FOR ORAL ARGUMENT by email to the electronic service addresses for Patent Owner and Petitioners in IPR2024-0009 and IPR2024-00107

J. Steven Baughman
Megan Raymond
Jenny C. Wu
Michael Milea
Philip S. May
Joshua Reich
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
steve.baughman@groombridgewu.com
megan.raymond@groombridgewu.com
jenny.wu@groombridgewu.com
mike.milea@groombridgewu.com
philip.may@groombridgewu.com
joshua.reich@groombridgewu.com

Novo-Semaglutide-
IPR@groombridgewu.com

Jovial Wong
Scott Border
WINSTON & STRAWN LLC
jwong@winston.com
sborder@winston.com

Brian Sodikoff
Christopher B. Ferenc
KATTEN MUCHIN ROSENMAN
LLP
brian.sodikoff@katten.com
christopher.ferenc@katten.com

Dated: July 12, 2024

PERKINS COIE LLP
700 Thirteenth Street, N.W., Suite 800
Washington, D.C. 20005-3960
202.654.6200 (phone)
202.654.6211 (fax)

/Brandon M. White/

Lead Counsel
Brandon M. White, Reg No. 52,354

Attorneys for Petitioner